MARKET

AVIR

AVIR

Atea Pharmaceuticals, Inc.
NASDAQ
3.200
-0.020
-0.62%
Closed 16:37 03/24 EDT
OPEN
3.260
PREV CLOSE
3.220
HIGH
3.290
LOW
3.180
VOLUME
154.63K
TURNOVER
0
52 WEEK HIGH
4.145
52 WEEK LOW
2.750
MARKET CAP
273.68M
P/E (TTM)
-1.6014
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AVIR last week (0317-0321)?
Weekly Report · 1d ago
ATEA PHARMACEUTICALS: BRADLEY L. RADOFF TO NOMINATE THREE DIRECTOR CANDIDATES TO STAND FOR ELECTION TO CO'S BOARD
Reuters · 3d ago
ATEA PHARMACEUTICALS INC - RECEIVES NOTICE OF DIRECTOR NOMINATIONS FROM BRADLEY L. RADOFF
Reuters · 3d ago
Press Release: Atea Pharmaceuticals Issues Statement Regarding Director Nominations
Dow Jones · 3d ago
Atea Pharmaceuticals Issues Statement Regarding Director Nominations
Barchart · 3d ago
Weekly Report: what happened at AVIR last week (0310-0314)?
Weekly Report · 03/17 09:08
Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential
Simply Wall St · 03/13 17:05
Weekly Report: what happened at AVIR last week (0303-0307)?
Weekly Report · 03/10 09:08
More
About AVIR
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in is conducting a Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of Coronavirus disease 2019 (COVID-19). It is also conducting a Phase 2 clinical trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). The bemnifosbuvir (AT-527), is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor that combines a unique nucleotide scaffold with novel double prodrugs for the intended purpose of inhibiting the enzymes central to viral replication. SUNRISE-3 is designed to evaluate bemnifosbuvir as monotherapy, but it is also exploring the effect of combination therapy in a smaller sub-set of patients.

Webull offers Atea Pharmaceuticals Inc stock information, including NASDAQ: AVIR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVIR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AVIR stock methods without spending real money on the virtual paper trading platform.